Literature DB >> 27553603

Intratumoral heterogeneity of CD44v6 in rectal cancer.

H-G Liu1,2,3, L Lv3, H Shen4,5.   

Abstract

PURPOSE: CD44v6 plays a controversial role in tumor progression and patient outcome in colorectal cancer by plenty of conflicting reports. The purpose of this study was to profile the intratumoral heterogeneity of CD44v6 in rectal cancer and investigate its role in lymph node metastasis.
METHODS: Sixty patients were included in this study. Immunohistochemistry for CD44v6 was performed in normal mucosa, primary tumor, and lymph node metastasis with whole tissue sections. The staining intensity in tumor center and invasive front was separately measured. Sampling bias was evaluated by quantitative real-time PCR with 15 pairs of frozen tissues from different sites of the primary tumor.
RESULTS: CD44v6 expression increased from normal mucosa to primary tumor to lymph node metastasis. Multiple intratumoral staining patterns was observed in primary tumor, and CD44v6 expression in invasive front was significantly higher than that in tumor center. In addition, mRNA expression levels differed across different geographical regions of the tumor. No association between CD44v6 expression and lymph node metastasis was revealed.
CONCLUSIONS: Substantial intratumoral heterogeneity of CD44v6 exists in rectal cancer that impacts the outcome of individual studies. CD44v6 expression should be assessed in a more precise way with a specified staining pattern and in a designated location.

Entities:  

Keywords:  CD44v6; Intratumoral heterogeneity; Metastasis; Rectal cancer

Mesh:

Substances:

Year:  2016        PMID: 27553603     DOI: 10.1007/s12094-016-1542-9

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  22 in total

1.  Decreased expression of CD44 splicing variants in advanced colorectal carcinomas.

Authors:  S Weg-Remers; M Anders; B von Lampe; E O Riecken; G Schüder; G Feifel; M Zeitz; A Stallmach
Journal:  Eur J Cancer       Date:  1998-09       Impact factor: 9.162

2.  E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer.

Authors:  R Bendardaf; A Elzagheid; H Lamlum; R Ristamäki; Y Collan; S Pyrhönen
Journal:  Oncol Rep       Date:  2005-05       Impact factor: 3.906

3.  Tumour heterogeneity in the clinic.

Authors:  Philippe L Bedard; Aaron R Hansen; Mark J Ratain; Lillian L Siu
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

4.  CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer.

Authors:  Seiya Saito; Hirohisa Okabe; Masayuki Watanabe; Takatsugu Ishimoto; Masaaki Iwatsuki; Yoshifumi Baba; Youhei Tanaka; Junji Kurashige; Yuji Miyamoto; Hideo Baba
Journal:  Oncol Rep       Date:  2013-02-05       Impact factor: 3.906

5.  CD44 variant isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports adhesion and apoptosis resistance.

Authors:  Pamela Klingbeil; Rachid Marhaba; Thorsten Jung; Robert Kirmse; Thomas Ludwig; Margot Zöller
Journal:  Mol Cancer Res       Date:  2009-02-10       Impact factor: 5.852

6.  Systematic assessment of the prognostic impact of membranous CD44v6 protein expression in colorectal cancer.

Authors:  Inti Zlobec; Ursula Günthert; Luigi Tornillo; Giandomenica Iezzi; Daniel Baumhoer; Luigi Terracciano; Alessandro Lugli
Journal:  Histopathology       Date:  2009-11       Impact factor: 5.087

7.  CD44v6 down-regulation is an independent prognostic factor for poor outcome of colorectal carcinoma.

Authors:  Lili Wang; Qin Liu; Dongliang Lin; Maode Lai
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

8.  Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes.

Authors:  Jacques B de Kok; Rian W Roelofs; Belinda A Giesendorf; Jeroen L Pennings; Erwin T Waas; Ton Feuth; Dorine W Swinkels; Paul N Span
Journal:  Lab Invest       Date:  2005-01       Impact factor: 5.662

Review 9.  The causes and consequences of genetic heterogeneity in cancer evolution.

Authors:  Rebecca A Burrell; Nicholas McGranahan; Jiri Bartek; Charles Swanton
Journal:  Nature       Date:  2013-09-19       Impact factor: 49.962

10.  Osteopontin-enhanced hepatic metastasis of colorectal cancer cells.

Authors:  Jianjin Huang; Chi Pan; Hanguang Hu; Shu Zheng; Ling Ding
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

View more
  3 in total

1.  Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy.

Authors:  Anja C Mortensen; Diana Spiegelberg; Anna-Karin Haylock; Hans Lundqvist; Marika Nestor
Journal:  Int J Oncol       Date:  2018-04-11       Impact factor: 5.650

Review 2.  Significance of alternative splicing in cancer cells.

Authors:  Fei Qi; Yong Li; Xue Yang; Yan-Ping Wu; Lian-Jun Lin; Xin-Min Liu
Journal:  Chin Med J (Engl)       Date:  2020-01-20       Impact factor: 2.628

3.  CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations.

Authors:  Ling Tang; Hongming Huang; Yutong Tang; Qing Li; Jue Wang; Dengju Li; Zhaodong Zhong; Ping Zou; Yong You; Yang Cao; Yingjie Kong; Anyuan Guo; Shu Zhou; Huimin Li; Fankai Meng; Yi Xiao; Xiaojian Zhu
Journal:  Clin Transl Med       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.